Smolen JS - Search Results

1

Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis.

Genovese MC, Kremer JM, Kartman CE, Schlichting DE, Xie L, Carmack T, Pantojas C, Sanchez Burson J, Tony HP, Macias WL, Rooney TP, Smolen JS. Genovese MC, et al. Among authors: smolen js. Rheumatology (Oxford). 2018 May 1;57(5):900-908. doi: 10.1093/rheumatology/kex489. Rheumatology (Oxford). 2018. PMID: 29415145 Free PMC article. Clinical Trial.

2

Recombinant human interferon gamma in the treatment of rheumatoid arthritis: double blind placebo controlled study.

Machold KP, Neumann K, Smolen JS. Machold KP, et al. Among authors: smolen js. Ann Rheum Dis. 1992 Sep;51(9):1039-43. doi: 10.1136/ard.51.9.1039. Ann Rheum Dis. 1992. PMID: 1417133 Free PMC article. Clinical Trial.

3

Folic acid and cyanocobalamin levels in serum and erythrocytes during low-dose methotrexate therapy of rheumatoid arthritis and psoriatic arthritis patients.

Leeb BF, Witzmann G, Ogris E, Studnicka-Benke A, Andel I, Schweitzer H, Smolen JS. Leeb BF, et al. Among authors: smolen js. Clin Exp Rheumatol. 1995 Jul-Aug;13(4):459-63. Clin Exp Rheumatol. 1995. PMID: 7586777 Clinical Trial.

4

Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis.

Steiner G, Studnicka-Benke A, Witzmann G, Höfler E, Smolen J. Steiner G, et al. J Rheumatol. 1995 Mar;22(3):406-12. J Rheumatol. 1995. PMID: 7783054

5

Early arthritis therapy: rationale and current approach.

Machold KP, Eberl G, Leeb BF, Nell V, Windisch B, Smolen JS. Machold KP, et al. Among authors: smolen js. J Rheumatol Suppl. 1998 Jul;53:13-9. J Rheumatol Suppl. 1998. PMID: 9666413 Review.

6

Cytokine production by synovial T cells in rheumatoid arthritis.

Steiner G, Tohidast-Akrad M, Witzmann G, Vesely M, Studnicka-Benke A, Gal A, Kunaver M, Zenz P, Smolen JS. Steiner G, et al. Among authors: smolen js. Rheumatology (Oxford). 1999 Mar;38(3):202-13. doi: 10.1093/rheumatology/38.3.202. Rheumatology (Oxford). 1999. PMID: 10325658

7

Sensitivity and specificity of anti-Sa autoantibodies for rheumatoid arthritis.

Hueber W, Hassfeld W, Smolen JS, Steiner G. Hueber W, et al. Among authors: smolen js. Rheumatology (Oxford). 1999 Feb;38(2):155-9. doi: 10.1093/rheumatology/38.2.155. Rheumatology (Oxford). 1999. PMID: 10342629

8

Recapitulation of the round-table discussion--assessing the role of anti-tumour necrosis factor therapy in the treatment of rheumatoid arthritis.

Furst DE, Keystone E, Maini RN, Smolen JS. Furst DE, et al. Among authors: smolen js. Rheumatology (Oxford). 1999 Nov;38 Suppl 2:50-3. Rheumatology (Oxford). 1999. PMID: 10646494

9

Efficacy and safety of the new DMARD leflunomide: comparison to placebo and sulfasalazine in active rheumatoid arthritis.

Smolen JS. Smolen JS. Scand J Rheumatol Suppl. 1999;112:15-21. doi: 10.1080/030097499750042245-1. Scand J Rheumatol Suppl. 1999. PMID: 10668523 Clinical Trial.

10

Development of a disease activity index for the assessment of reactive arthritis (DAREA).

Eberl G, Studnicka-Benke A, Hitzelhammer H, Gschnait F, Smolen JS. Eberl G, et al. Among authors: smolen js. Rheumatology (Oxford). 2000 Feb;39(2):148-55. doi: 10.1093/rheumatology/39.2.148. Rheumatology (Oxford). 2000. PMID: 10725064

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

830 results

Search Page

Filters